Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory cross-sectional study of cerebrospinal fluid virological suppression and neurocognitive status in HIV-1 patients on long-term lopinavir/ritonavir monotherapy versus lopinavir/ritonavir + emtricitabine/tenofovir
2010-019446-38Phase 4Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Mar 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lopinavir, ritonavir, emtricitabine and tenofovir in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Ultrasensitive HIV-1 RNA in cerebrospinal fluid. Started Mar 2010; status: completed.
02
Drugs
lopinavirritonaviremtricitabinetenofovir
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-019446-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019446-38.